BACKGROUND: The impact of polyvascular disease (peripheral arterial disease [PAD] and cerebrovascular disease [CVD]) on long-term cardiovascular outcomes among older patients with acute myocardial infarction has not been well studied. METHODS AND RESULTS: Patients with non-ST-segment-elevation myocardial infarction aged ≥65 years from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines) registry who survived to hospital discharge were linked to longitudinal data from the Centers for Medicare & Medicaid Services (n=34 205). All patients were presumed to have coronary artery disease (CAD) and were classified into the following 4 groups: 10.7% with prior CVD (CAD+CVD group); 11.5% with prior PAD (CAD+PAD); 3.1% with prior PAD and CVD (CAD+PAD+CVD); and 74.7% with no polyvascular disease (CAD alone). Cox proportional hazards modeling was used to examine the hazard of long-term mortality and composite of death or readmission for myocardial infarction or stroke (median follow-up, 35 months; interquartile range, 17-49 months). Compared with the CAD alone group, patients with polyvascular disease had greater comorbidities, were less likely to undergo revascularization, and received less often recommended discharge interventions. Three-year mortality rates increased with number of arterial bed involvement as follows: 33% for CAD alone, 49% for CAD+PAD, 52% for CAD+CVD, and 59% for CAD+PAD+CVD. Relative to the CAD alone group, patients with all 3 arterial beds involved had the highest risk of long-term mortality (adjusted hazard ratio [95% CI], 1.49 [1.38-1.61]; CAD+CVD, 1.38 [1.31-1.44]; CAD+PAD, 1.29 [1.23-1.35]). Similarly, the risk of long-term composite ischemic events was highest among patients in the CAD+PAD+CVD group. CONCLUSIONS: Among older patients with non-ST-segment-elevation myocardial infarction, those with polyvascular disease have substantially higher long-term risk for recurrent events or death. Future studies targeting greater adherence to secondary prevention strategies and novel therapies are needed to help to reduce long-term cardiovascular events in this vulnerable population.
BACKGROUND: The impact of polyvascular disease (peripheral arterial disease [PAD] and cerebrovascular disease [CVD]) on long-term cardiovascular outcomes among older patients with acute myocardial infarction has not been well studied. METHODS AND RESULTS:Patients with non-ST-segment-elevation myocardial infarction aged ≥65 years from the CRUSADE (Can Rapid Risk Stratification of Unstable AnginaPatients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines) registry who survived to hospital discharge were linked to longitudinal data from the Centers for Medicare & Medicaid Services (n=34 205). All patients were presumed to have coronary artery disease (CAD) and were classified into the following 4 groups: 10.7% with prior CVD (CAD+CVD group); 11.5% with prior PAD (CAD+PAD); 3.1% with prior PAD and CVD (CAD+PAD+CVD); and 74.7% with no polyvascular disease (CAD alone). Cox proportional hazards modeling was used to examine the hazard of long-term mortality and composite of death or readmission for myocardial infarction or stroke (median follow-up, 35 months; interquartile range, 17-49 months). Compared with the CAD alone group, patients with polyvascular disease had greater comorbidities, were less likely to undergo revascularization, and received less often recommended discharge interventions. Three-year mortality rates increased with number of arterial bed involvement as follows: 33% for CAD alone, 49% for CAD+PAD, 52% for CAD+CVD, and 59% for CAD+PAD+CVD. Relative to the CAD alone group, patients with all 3 arterial beds involved had the highest risk of long-term mortality (adjusted hazard ratio [95% CI], 1.49 [1.38-1.61]; CAD+CVD, 1.38 [1.31-1.44]; CAD+PAD, 1.29 [1.23-1.35]). Similarly, the risk of long-term composite ischemic events was highest among patients in the CAD+PAD+CVD group. CONCLUSIONS: Among older patients with non-ST-segment-elevation myocardial infarction, those with polyvascular disease have substantially higher long-term risk for recurrent events or death. Future studies targeting greater adherence to secondary prevention strategies and novel therapies are needed to help to reduce long-term cardiovascular events in this vulnerable population.
Authors: Frederick A Spencer; Darleen Lessard; Chyke Doubeni; Jorge Yarzebski; Joel M Gore; Robert J Goldberg Journal: Am Heart J Date: 2007-01 Impact factor: 4.749
Authors: James B Froehlich; Debabrata Mukherjee; Alvaro Avezum; Andrzej Budaj; Eva M Kline-Rogers; José López-Sendón; Jeanna Allegrone; Kim A Eagle; Rajendra H Mehta; Robert J Goldberg Journal: Am Heart J Date: 2006-05 Impact factor: 4.749
Authors: Jacqueline Saw; Deepak L Bhatt; David J Moliterno; Sorin J Brener; Steven R Steinhubl; A Michael Lincoff; James E Tcheng; Robert A Harrington; Maarten Simoons; TingFei Hu; Mobeen A Sheikh; Dean J Kereiakes; Eric J Topol Journal: J Am Coll Cardiol Date: 2006-09-26 Impact factor: 24.094
Authors: K Sutton-Tyrrell; C Rihal; M A Sellers; K Burek; J Trudel; G Roubin; M M Brooks; M Grogan; G Sopko; N Keller; R Jandová Journal: Am J Cardiol Date: 1998-02-15 Impact factor: 2.778
Authors: Elena Birman-Deych; Amy D Waterman; Yan Yan; David S Nilasena; Martha J Radford; Brian F Gage Journal: Med Care Date: 2005-05 Impact factor: 2.983
Authors: Mandeep Singh; Ryan J Lennon; Dawood Darbar; Bernard J Gersh; David R Holmes; Charanjit S Rihal Journal: Mayo Clin Proc Date: 2004-09 Impact factor: 7.616
Authors: Daniel J O'Rourke; Hebe B Quinton; Winthrop Piper; Felix Hernandez; Jeremy Morton; Bruce Hettleman; Michael Hearne; William Nugent; Gerald T O'Connor; David J Malenka Journal: Ann Thorac Surg Date: 2004-08 Impact factor: 4.330
Authors: Harm H H Feringa; Virginie H van Waning; Jeroen J Bax; Abdou Elhendy; Eric Boersma; Olaf Schouten; Wael Galal; Radosav V Vidakovic; Marco J Tangelder; Don Poldermans Journal: J Am Coll Cardiol Date: 2006-02-23 Impact factor: 24.094
Authors: Alan T Hirsch; Ziv J Haskal; Norman R Hertzer; Curtis W Bakal; Mark A Creager; Jonathan L Halperin; Loren F Hiratzka; William R C Murphy; Jeffrey W Olin; Jules B Puschett; Kenneth A Rosenfield; David Sacks; James C Stanley; Lloyd M Taylor; Christopher J White; John White; Rodney A White; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Sharon A Hunt; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel Journal: Circulation Date: 2006-03-21 Impact factor: 29.690
Authors: Manesh R Patel; Michael S Conte; Donald E Cutlip; Nabil Dib; Patrick Geraghty; William Gray; William R Hiatt; Mami Ho; Koji Ikeda; Fumiaki Ikeno; Michael R Jaff; W Schuyler Jones; Masayuki Kawahara; Robert A Lookstein; Roxana Mehran; Sanjay Misra; Lars Norgren; Jeffrey W Olin; Thomas J Povsic; Kenneth Rosenfield; John Rundback; Fadi Shamoun; James Tcheng; Thomas T Tsai; Yuka Suzuki; Pascal Vranckx; Bret N Wiechmann; Christopher J White; Hiroyoshi Yokoi; Mitchell W Krucoff Journal: J Am Coll Cardiol Date: 2015-03-10 Impact factor: 24.094
Authors: Pil Sang Song; Dong Ryeol Ryu; Min Jeong Kim; Ki Hyun Jeon; Rak Kyeong Choi; Jin Sik Park; Young Bin Song; Joo Yong Hahn; Hyeon Cheol Gwon; Youngkeun Ahn; Myung Ho Jeong; Seung Hyuk Choi Journal: Korean Circ J Date: 2018-06 Impact factor: 3.243